Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 03-May-24 6:31 PM View:  | Moore John R General Counsel | Edgewise Therapeutics, Inc. (EWTX) | 02-May-24 | Option Sale | 1,956 | $18.91 | $36,988.00 | (38%) 5.21K to 3.25K | |
| 03-May-24 6:30 PM View: | Carruthers R Michael Chief Financial Officer | Edgewise Therapeutics, Inc. (EWTX) | 02-May-24 | Option Sale | 2,157 | $18.91 | $40,788.90 | (6%) 37.39K to 35.23K | |
| 03-May-24 6:29 PM View: | Derakhshan Behrad Chief Business Officer | Edgewise Therapeutics, Inc. (EWTX) | 02-May-24 | Option Sale | 1,718 | $18.91 | $32,487.40 | (11%) 15.14K to 13.42K | |
| 03-May-24 6:28 PM View: | Russell Alan J Chief Scientific Officer Director | Edgewise Therapeutics, Inc. (EWTX) | 02-May-24 | Option Sale | 1,576 | $18.91 | $29,802.20 | (18%) 8.81K to 7.24K | |
| 03-May-24 6:27 PM View: | Donovan Joanne M. CMO | Edgewise Therapeutics, Inc. (EWTX) | 02-May-24 | Option Sale | 3,682 | $18.91 | $69,626.60 | (16%) 23.58K to 19.9K | |
| 03-May-24 6:26 PM View: | Koch Kevin President and CEO Director | Edgewise Therapeutics, Inc. (EWTX) | 02-May-24 | Option Sale | 3,152 | $18.91 | $59,604.30 | (< 1%) 356.41K to 353.26K | |
| 03-May-24 6:29 PM View: | Derakhshan Behrad Chief Business Officer | Edgewise Therapeutics, Inc. (EWTX) | 01-May-24 | Option Exercise | 5,208 | -- | -- | 52% 9.93K to 15.14K | |
| 03-May-24 6:28 PM View: | Russell Alan J Chief Scientific Officer Director | Edgewise Therapeutics, Inc. (EWTX) | 01-May-24 | Option Exercise | 5,208 | -- | -- | 144% 3.61K to 8.81K | |
| 03-May-24 6:27 PM View: | Donovan Joanne M. CMO | Edgewise Therapeutics, Inc. (EWTX) | 01-May-24 | Option Exercise | 10,417 | -- | -- | 79% 13.16K to 23.58K | |
| 03-May-24 6:26 PM View: | Koch Kevin President and CEO Director | Edgewise Therapeutics, Inc. (EWTX) | 01-May-24 | Option Exercise | 10,417 | -- | -- | 3% 346.0K to 356.41K | |
| 03-May-24 6:30 PM View: | Carruthers R Michael Chief Financial Officer | Edgewise Therapeutics, Inc. (EWTX) | 01-May-24 | Option Exercise | 5,208 | -- | -- | 16% 32.18K to 37.39K | |
| 03-May-24 6:31 PM View: | Moore John R General Counsel | Edgewise Therapeutics, Inc. (EWTX) | 01-May-24 | Option Exercise | 5,208 | -- | -- | 100% 0 to 5.21K | |
| 09-Feb-24 5:43 PM View: | Moore John R General Counsel | Edgewise Therapeutics, Inc. (EWTX) | 09-Feb-24 | Option Exercise | 8,029 | $1.93 | $15,496.00 | 100% 0 to 8.03K | |
| 09-Feb-24 5:43 PM View: | Moore John R General Counsel | Edgewise Therapeutics, Inc. (EWTX) | 09-Feb-24 | Option Sale | 8,029 | $20.01 | $160,657.00 | (100%) 8.03K to 0 | |
| 09-Feb-24 5:42 PM View: | Derakhshan Behrad Chief Business Officer | Edgewise Therapeutics, Inc. (EWTX) | 09-Feb-24 | Option Exercise | 4,800 | $1.93 | $9,264.00 | 68% 7.02K to 11.82K | |
| 09-Feb-24 5:42 PM View: | Derakhshan Behrad Chief Business Officer | Edgewise Therapeutics, Inc. (EWTX) | 09-Feb-24 | Option Sale | 4,800 | $20.04 | $96,209.30 | (41%) 11.82K to 7.02K | |
| 09-Feb-24 5:43 PM View: | Moore John R General Counsel | Edgewise Therapeutics, Inc. (EWTX) | 08-Feb-24 | Option Sale | 3,813 | $20.01 | $76,284.80 | (100%) 3.81K to 0 | |
| 09-Feb-24 5:42 PM View: | Derakhshan Behrad Chief Business Officer | Edgewise Therapeutics, Inc. (EWTX) | 08-Feb-24 | Option Exercise | 4,600 | $1.93 | $8,878.00 | 66% 7.02K to 11.62K | |
| 09-Feb-24 5:42 PM View: | Derakhshan Behrad Chief Business Officer | Edgewise Therapeutics, Inc. (EWTX) | 08-Feb-24 | Option Sale | 4,600 | $20.01 | $92,048.80 | (40%) 11.62K to 7.02K | |
| 09-Feb-24 5:43 PM View: | Moore John R General Counsel | Edgewise Therapeutics, Inc. (EWTX) | 08-Feb-24 | Option Exercise | 3,813 | $1.93 | $7,359.09 | 100% 0 to 3.81K | |
| 09-Feb-24 5:42 PM View: | Derakhshan Behrad Chief Business Officer | Edgewise Therapeutics, Inc. (EWTX) | 07-Feb-24 | Option Exercise | 600 | $1.93 | $1,158.00 | 9% 7.02K to 7.62K | |
| 09-Feb-24 5:42 PM View: | Derakhshan Behrad Chief Business Officer | Edgewise Therapeutics, Inc. (EWTX) | 07-Feb-24 | Option Sale | 600 | $20.00 | $12,000.00 | (8%) 7.62K to 7.02K | |
| 09-Feb-24 5:43 PM View: | Moore John R General Counsel | Edgewise Therapeutics, Inc. (EWTX) | 07-Feb-24 | Option Exercise | 17,993 | $1.93 | $34,726.50 | 100% 0 to 17.99K | |
| 09-Feb-24 5:43 PM View: | Moore John R General Counsel | Edgewise Therapeutics, Inc. (EWTX) | 07-Feb-24 | Option Sale | 17,993 | $20.00 | $359,864.00 | (100%) 17.99K to 0 | |
| 25-Jan-24 4:46 PM View: | Carruthers R Michael Chief Financial Officer | Edgewise Therapeutics, Inc. (EWTX) | 23-Jan-24 | Option Exercise | 90,000 | $1.93 | $173,700.00 | 310% 29.02K to 119.02K | |
| 25-Jan-24 4:32 PM View: | Thompson Peter A Director 10% Owner | Edgewise Therapeutics, Inc. (EWTX) | 23-Jan-24 | Private Purchase Duplicate | 454,545 | $11.00 | $5,000,000.00 | 3% 14.3M to 14.76M | |
| 25-Jan-24 4:46 PM View: | Carruthers R Michael Chief Financial Officer | Edgewise Therapeutics, Inc. (EWTX) | 23-Jan-24 | Option Sale | 90,000 | $15.78 | $1,419,760.00 | (76%) 119.02K to 29.02K | |
| 25-Jan-24 4:28 PM View: | Orbimed Advisors LLC Director 10% Owner | Edgewise Therapeutics, Inc. (EWTX) | 23-Jan-24 | Private Purchase | 454,545 | $11.00 | $5,000,000.00 | 3% 14.3M to 14.76M | |
| 28-Dec-23 4:39 PM View: | Moore John R General Counsel | Edgewise Therapeutics, Inc. (EWTX) | 27-Dec-23 | Sale (Planned) | 8,497 | $10.50 | $89,218.50 | (100%) 8.5K to 0 | |
| 28-Dec-23 4:39 PM View: | Fox Jonathan C Director | Edgewise Therapeutics, Inc. (EWTX) | 26-Dec-23 | Private Purchase | 10,857 | $9.30 | $100,958.00 | 100% 0 to 10.86K | |
| 28-Dec-23 4:38 PM View: | Russell Alan J Chief Scientific Officer Director | Edgewise Therapeutics, Inc. (EWTX) | 26-Dec-23 | Sale | 172,585 | $9.33 | $1,610,100.00 | (98%) 176.19K to 3.61K | |
| 26-Jun-23 4:28 PM View: | Carruthers R Michael Chief Financial Officer | Edgewise Therapeutics, Inc. (EWTX) | 22-Jun-23 | Option Exercise | 10,000 | $0.71 | $7,100.00 | 53% 19.02K to 29.02K | |
| 03-May-23 10:00 PM View: | Donovan Joanne M. CMO | Edgewise Therapeutics, Inc. (EWTX) | 02-May-23 | Option Sale | 3,254 | $8.90 | $28,976.50 | (25%) 13.21K to 9.96K | |
| 03-May-23 10:00 PM View: | Moore John R General Counsel | Edgewise Therapeutics, Inc. (EWTX) | 02-May-23 | Option Sale | 1,897 | $8.90 | $16,892.60 | (22%) 8.46K to 6.57K | |
| 03-May-23 10:00 PM View: | Koch Kevin President and CEO Director | Edgewise Therapeutics, Inc. (EWTX) | 02-May-23 | Option Sale | 3,203 | $8.90 | $28,522.40 | (< 1%) 349.2K to 346.0K | |
| 03-May-23 10:00 PM View: | Carruthers R Michael Chief Financial Officer | Edgewise Therapeutics, Inc. (EWTX) | 02-May-23 | Option Sale | 1,336 | $8.90 | $11,896.90 | (8%) 17.46K to 16.13K | |
| 03-May-23 10:00 PM View: | Russell Alan J Chief Scientific Officer Director | Edgewise Therapeutics, Inc. (EWTX) | 02-May-23 | Option Sale | 1,602 | $8.90 | $14,265.60 | (< 1%) 177.79K to 176.19K | |
| 03-May-23 10:00 PM View: | Derakhshan Behrad Chief Business Officer | Edgewise Therapeutics, Inc. (EWTX) | 02-May-23 | Option Sale | 1,747 | $8.90 | $15,556.90 | (20%) 8.77K to 7.02K | |
| 03-May-23 10:00 PM View: | Carruthers R Michael Chief Financial Officer | Edgewise Therapeutics, Inc. (EWTX) | 01-May-23 | Option Exercise | 5,208 | -- | -- | 43% 12.25K to 17.46K | |
| 03-May-23 10:00 PM View: | Russell Alan J Chief Scientific Officer Director | Edgewise Therapeutics, Inc. (EWTX) | 01-May-23 | Option Exercise | 5,208 | -- | -- | 3% 172.59K to 177.79K | |
| 03-May-23 10:00 PM View: | Derakhshan Behrad Chief Business Officer | Edgewise Therapeutics, Inc. (EWTX) | 01-May-23 | Option Exercise | 5,208 | -- | -- | 146% 3.56K to 8.77K | |
| 03-May-23 10:00 PM View: | Moore John R General Counsel | Edgewise Therapeutics, Inc. (EWTX) | 01-May-23 | Option Exercise | 5,208 | -- | -- | 160% 3.25K to 8.46K | |
| 03-May-23 10:00 PM View: | Donovan Joanne M. CMO | Edgewise Therapeutics, Inc. (EWTX) | 01-May-23 | Option Exercise | 10,416 | -- | -- | 372% 2.8K to 13.21K | |
| 03-May-23 10:00 PM View: | Koch Kevin President and CEO Director | Edgewise Therapeutics, Inc. (EWTX) | 01-May-23 | Option Exercise | 10,416 | -- | -- | 3% 338.78K to 349.2K | |
| 05-Oct-22 4:42 PM View: | Moore John R General Counsel | Edgewise Therapeutics, Inc. (EWTX) | 03-Oct-22 | Option Exercise | 4,730 | $1.93 | $9,128.90 | 158% 3.0K to 7.73K | |
| 05-Oct-22 4:42 PM View: | Moore John R General Counsel | Edgewise Therapeutics, Inc. (EWTX) | 03-Oct-22 | Planned Option Sale | 4,730 | $9.76 | $46,154.90 | (61%) 7.73K to 3.0K | |
| 16-Sep-22 4:31 PM View: | Orbimed Advisors LLC Director 10% Owner | Edgewise Therapeutics, Inc. (EWTX) | 16-Sep-22 | Private Purchase | 484,496 | $10.32 | $5,000,000.00 | 4% 13.82M to 14.3M | |
| 16-Sep-22 4:34 PM View: | Thompson Peter A Director 10% Owner | Edgewise Therapeutics, Inc. (EWTX) | 16-Sep-22 | Private Purchase Duplicate | 484,496 | $10.32 | $5,000,000.00 | 4% 13.82M to 14.3M | |
| 16-Sep-22 2:35 PM View: | Novo A/s 10% Owner | Edgewise Therapeutics, Inc. (EWTX) | 14-Sep-22 | Private Purchase | 484,496 | $10.32 | $5,000,000.00 | 9% 5.59M to 6.07M | |
| 08-Sep-22 4:16 PM View: | Moore John R General Counsel | Edgewise Therapeutics, Inc. (EWTX) | 06-Sep-22 | Planned Option Sale | 4,730 | $10.91 | $51,597.70 | (61%) 7.73K to 3.0K |
